Device Trial Radar · NCT05354297
Evidence for Health Improvement in People With Diabetes Using One Touch & Partner Solutions
Last checked: Nov 20, 2026Latest source record: Jul 20, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
800
Planned (sponsor's estimate)
Start
Jul 26, 2022
Primary completion
Apr 1, 2023
Study completion Sep 1, 2023
Sponsor
- Lead sponsor
- LifeScanNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Evidation Health
- First posted
- Apr 29, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ECLIPSE will evaluate the clinical and economic value of OneTouch Solutions in a real world study design. OneTouch Solutions describes a selection of devices and health and wellness solutions that people with diabetes (PWDs) can access online via OneTouch Solutions (Cecelia Health, Fitbit, Noom or Welldoc, each in combination with OneTouch Verio Reflect® blood glucose meter and the OneTouch Reveal® mobile app (or Welldoc app for the Welldoc arm)). ECLIPSE is a large parallel arm digital health study combining advanced blood glucose monitoring solutions with a choice of four different health and wellness applications or services. There are four unique study arms that will run in parallel over one year. The primary (A1c) endpoint for each study arm will be after 6 months and subjects will continue to use the interventions for a full year to generate data on sustained engagement with these products and services, and to collect healthcare utilization and health insurance claims information. Each study arm will differ to some degree in terms of patient baseline demographics (since subjects self-select their own app/intervention) and the experience per arm will be unique, and therefore each study arm will be analysed separately in terms of endpoints and outcomes.
Conditions
- Diabetes Mellitus, Type 2
Interventions
Cecelia Health plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile appDevice
Expert guidance via coaching
Fitbit plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile appDevice
Fitness and wellness guidance
Noom plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile appDevice
Behavioral weight loss program
Welldoc plus OneTouch Verio Reflect® BGM and Welldoc appDevice
Multi condition support
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in A1c from screening to 3 and 6 months in each of the OneTouch Solutions programsTime frame: 3 and 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Evidation Health
San Mateo, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.